Real-World Outcomes

The results from a randomized controlled trial were compared with a real-world cohort for the safety and efficacy of a biosimilar to treat chemotherapy-induced neutropenia in patients with breast cancer.
A new study sought to better define real-world initiation, management, and outcomes of patients with chronic lymphocytic leukemia treated with a standard-of-care therapy.
Widespread use of alternative payment models may improve the quality of breast and colorectal cancer screening programs.
Socioeconomic inequalities may affect cancer-specific survival and overall survival in patients with squamous cell carcinoma of the anus.
A new study suggests the strength of evidence cited by the National Comprehensive Cancer Network to support recommendations deviating from FDA-approved therapy recommendations is not robust.
A National Cancer Database analysis revealed racial and ethnic disparities in patients with gastric cancer in the use of preoperative chemotherapy and in outcomes.
Despite significant treatment advancements in the management of multiple myeloma over the last 20 years, racial disparities in health care access and survival continue to exist.
In recent years, there has been a significant increase in hospitalizations, readmissions, and deaths due to immune-related adverse events from immune checkpoint inhibitors, according to a presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium.
A recent survey highlighted the need for educational resources to go further in-depth into immunotherapy science and management strategies for treatment-related adverse events.
The growing use of effective treatment strategies for metastatic cancer in the brain has not been documented in certain patient populations.